Lifecore inks biomaterial deal:
This article was originally published in Clinica
Lifecore Biomedical has entered into exclusive licence and development agreements with the Cleveland Clinic, in Ohio, to develop and commercialise hyaluronan-based products and related applications. It has licensed a patented hyaluronan-based cross-linking technology that can be used for products in aesthetics, orthopaedics, ophthalmology and other medical fields. The biomaterial is formed through a chemical reaction, catalysed by a naturally occurring molecule, which provides a spectrum of formulations that are stable, well-tolerated by the body, and able to mimic the function of a wide variety of tissues, while providing for tissue repair and reinforcement, said the Chaska, Minnesota firm. Lifecore believes the technology platform will allow it to expand in its existing markets and enter new markets.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.